The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial
Open accessAbstract
PURPOSE: For patients with resectable stage IIIA(N2) non–small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% in the SAKK 16/00 trial and is an accepted standard of care. We investigated the additional benefit of perioperative treatment with durvalumab. METHODS: Neoadjuvant treatment consisted of three cycles of cisplatin 100 mg/m 2 and docetaxel 85 mg/m 2 once every 3 weeks followed by two doses of durvalumab 750 mg once every 2 weeks. Durvalumab was continued for 1 year after surgery. The primary end point was 1-year EFS. The hypothesis for statistical considerations was an improvement of 1-year EFS from 48% to 65%. RESULTS: Sixty-eight patients were enrolled, 67 were included in the full analysis set. Radiographic response rate was 43% (95% CI, 31 to 56) after neoadjuvant chemotherapy and 58% (95% CI, 45 to 71) after sequential neoadjuvant immunotherapy. Fifty-five patients were resected, of which 34 (62%) achieved a major pathologic response (MPR; ≤ 10% viable tumor cells) and 10 (18%) among them a complete pathologic response. Postoperative nodal downstaging (ypN0-1) was observed in 37 patients (67%). Fifty-one (93%) resected patients had an R0 resection. There was no significant effect of pretreatment PD-L1 expression on MPR or nodal downstaging. The 1-year EFS rate was 73% (two-sided 90% CI, 63 to 82). Median EFS and overall survival were not reached after 28.6 months of median follow-up. Fifty-nine (88%) patients had an adverse event grade ≥ 3 including two fatal adverse events that were judged not to be treatment-related. CONCLUSION: The addition of perioperative durvalumab to neoadjuvant chemotherapy in patients with stage IIIA(N2) non–small-cell lung cancer is safe and exceeds historical data of chemotherapy alone with a high MPR and an encouraging 1-year EFS rate of 73%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Goldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W. E. E., Nicholson, A. G., Groome, P., Mitchell, A., Bolejack, V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.009 · Cited by 4,607
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Albain, K. S., Swann, R. S., Rusch, V. W., Turrisi, A. T., Shepherd, F. A., Smith, C., Chen, Y., Livingston, R. B., Feins, R. H., Gandara, D. R., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60737-6 · Cited by 1,470
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880
Provencio, M., Nadal, E., Insa, A., García-Campelo, M. R., Casal-Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., De Castro Carpeño, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30453-8 · Cited by 841
Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Shu, C. A., Gainor, J. F., Awad, M. M., Chiuzan, C., Grigg, C. M., Pabani, A., Garofano, R. F., Stoopler, M. B., Cheng, S. K., White, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30140-6 · Cited by 623
Cascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01224-2 · Cited by 618 · cited 1×
“One recent trial evaluating 6 weeks of neoadjuvant nivolumab and ipilimumab treatment was terminated early after inclusion of nine patients only because of a high rate of treatment-related AEs grade $ 3 and 3 patients with biopsy-confirmed tumor progression precluding surgery,(29) whereas in the NEOSTAR trial, 17 of 2…”
ResultComplete resection in lung cancer surgery: proposed definition
Rami-Porta, R., Wittekind, C., & Goldstraw, P. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.01.001 · Cited by 495
Travis, W. D., Dacic, S., Wistuba, I., Sholl, L., Adusumilli, P., Bubendorf, L., Bunn, P., Cascone, T., Chaft, J., Chen, G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.005 · Cited by 465
Self-citationBetticher, D. C., Hsu Schmitz, S.-F., Tötsch, M., Hansen, E., Joss, C., von Briel, C., Schmid, R. A., Pless, M., Habicht, J., Roth, A. D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.040 · Cited by 449
Self-citationNeoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
Gao, S., Li, N., Gao, S., Xue, Q., Ying, J., Wang, S., Tao, X., Zhao, J., Mao, Y., Wang, B., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.017 · Cited by 401
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
Pless, M., Stupp, R., Ris, H.-B., Stahel, R. A., Weder, W., Thierstein, S., Gerard, M.-A., Xyrafas, A., Früh, M., Cathomas, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60294-x · Cited by 390
Self-citationEberhardt, W. E. E., Pöttgen, C., Gauler, T. C., Friedel, G., Veit, S., Heinrich, V., Welter, S., Budach, W., Spengler, W., Kimmich, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6812 · Cited by 365
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
(2018) · New England Journal of Medicine · doi:10.1056/nejmc1808251 · Cited by 277
for the Swiss Group for Clinical Cancer Research (SAKK), B., Betticher, D. C., Hsu Schmitz, S.-F., Tötsch, M., Hansen, E., Joss, C., von Briel, C., Schmid, R. A., Pless, M., Habicht, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603075 · Cited by 207
Self-citationGrading of Tumor Regression in Non-small Cell Lung Cancer
Junker, K., Langner, K., Klinke, F., Bosse, U., & Thomas, M. (2001) · Chest · doi:10.1378/chest.120.5.1584 · Cited by 176
Remon, J., Passiglia, F., Ahn, M.-J., Barlesi, F., Forde, P. M., Garon, E. B., Gettinger, S., Goldberg, S. B., Herbst, R. S., Horn, L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.006 · Cited by 169
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
Reuss, J. E., Anagnostou, V., Cottrell, T. R., Smith, K. N., Verde, F., Zahurak, M., Lanis, M., Murray, J. C., Chan, H. Y., McCarthy, C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001282 · Cited by 165
Kwiatkowski, D. J., Rusch, V. W., Chaft, J. E., Johnson, B. E., Nicholas, A., Wistuba, I. I., Merritt, R., Lee, J. M., Bunn, P. A., Tang, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.8503 · Cited by 146
Cascone, T., William, W. N., Weissferdt, A., Lin, H. Y., Leung, C. H., Carter, B. W., Fossella, F. V., Mott, F. E., Papadimitrakopoulou, V. A., Blumenschein, G. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.8504 · Cited by 144
Pechoux, C. L., Pourel, N., Barlési, F., Finn, C. F., Lerouge, D., Zalcman, G., Antoni, D., Lamezec, B., Nestle, U., Boisselier, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2280 · Cited by 94
Wislez, M., Mazières, J., Lavolé, A., Zalcman, G., Carre, O., Egenod, T., Caliandro, R., Gervais, R., Jeannin, G., Molinier, O., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1416 · Cited by 57
Cited by
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
Chaft, J. E., Rimner, A., Weder, W., Azzoli, C. G., Kris, M. G., & Cascone, T. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00501-4 · Cited by 375
Self-citationProvencio, M., Serna-Blasco, R., Nadal, E., Insa, A., García-Campelo, M. R., Casal Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02660 · Cited by 349
Magnesium sensing via LFA-1 regulates CD8+ T cell effector function
Lötscher, J., Martí i Líndez, A.-A., Kirchhammer, N., Cribioli, E., Giordano Attianese, G. M. P., Trefny, M. P., Lenz, M., Rothschild, S. I., Strati, P., Künzli, M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.039 · Cited by 277
Self-citationNon-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Mithoowani, H., & Febbraro, M. (2022) · Current Oncology · doi:10.3390/curroncol29030150 · Cited by 259
Metadata
- Authors
- Rothschild, S. I., Zippelius, A., Eboulet, E. I., Savic Prince, S., Betticher, D., Bettini, A., Früh, M., Joerger, M., Lardinois, D., Gelpke, H., Mauti, L. A., Britschgi, C., Weder, W., Peters, S., Mark, M., Cathomas, R., Ochsenbein, A. F., Janthur, W.-D., Waibel, C., Mach, N., Froesch, P., Buess, M., Bohanes, P., Godar, G., Rusterholz, C., Gonzalez, M., Pless, M., & for the Swiss Group for Clinical Cancer Research (SAKK)
- Venue
- Journal of Clinical Oncology
- Published
- 2021-09-10
- Volume
- 39
- Issue
- 26
- Pages
- 2872-2880
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3178223947
- Cited by
- 333
- References
- 27
- FWCI
- 36.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.